Sanofi cancels development of fedratinib for Myelofibrosis
Sanofi announced the decision to halt all clinical trials and cancel plans for regulatory filings with its investigational JAK2 inhibitor, fedratinib (SAR302503).Following a thorough risk-benefit analysis, including consultation with the FDA, study investigators, independent expert neurologists and neuro-radiologists,Sanofi determined that the risk to patient safety outweighed the benefit that fedratinib would bring to patients. This decision follows recent reports of cases consistent with Wernicke�s encephalopathy in patients participating in fedratinib clinical trials.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.